These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 24543716)

  • 1. [Ophthalmic solutions].
    KEDVESSY G
    Gyogyszeresz; 1955 May; 10(5):90-4. PubMed ID: 24543716
    [No Abstract]   [Full Text] [Related]  

  • 2. Ophthalmic solutions.
    EIDSMOE CT
    SD J Med Pharm; 1956 Jan; 9(1):40-8. PubMed ID: 13290948
    [No Abstract]   [Full Text] [Related]  

  • 3. The clinical significance of the pH of ophthalmic solutions.
    FLOYD G; KRONFELD PC; MCDONALD JE
    J Am Pharm Assoc Am Pharm Assoc; 1953 Jun; 42(6):333-7. PubMed ID: 13069313
    [No Abstract]   [Full Text] [Related]  

  • 4. Preservation of ophthalmic solutions; a critical evaluation.
    FRITH ML; WRIGHT SE
    Br J Ophthalmol; 1955 Mar; 39(3):174-7. PubMed ID: 14363614
    [No Abstract]   [Full Text] [Related]  

  • 5. Preparation and maintenance of sterile ophthalmic solutions.
    THEODORE FH; FEINSTEIN RR
    J Am Med Assoc; 1953 Aug; 152(17):1631-3. PubMed ID: 13069233
    [No Abstract]   [Full Text] [Related]  

  • 6. [Dihexamidine collyrium in infections of the eye and its appendages].
    MAWAS E; BEGUE JJ
    Bull Soc Ophtalmol Fr; 1962 Jun; 62():361-6. PubMed ID: 13934049
    [No Abstract]   [Full Text] [Related]  

  • 7. Survey on eye comfort in aircraft: II. Use of ophthalmic solutions.
    Eng WG
    Aviat Space Environ Med; 1979 Nov; 50(11):1166-9. PubMed ID: 526219
    [TBL] [Abstract][Full Text] [Related]  

  • 8. STERILITY of ophthalmic solutions.
    Eye Ear Nose Throat Mon; 1953 May; 32(5):263; passim. PubMed ID: 13043611
    [No Abstract]   [Full Text] [Related]  

  • 9. [Remarks on the present-day status of the technology of injectable solutions and eye drops in the drug stores of the German Democratic Republic and proposals for its improvement].
    HORSCH W
    Pharm Prax; 1963; 2():21-3. PubMed ID: 13954997
    [No Abstract]   [Full Text] [Related]  

  • 10. Phenylethyl alcohol as a bacteriostatic agent in ophthalmic solutions.
    BREWER JH; GOLDSTEIN SW; McLAUGHLIN CB
    J Am Pharm Assoc Am Pharm Assoc; 1953 Sep; 42(9):584-5. PubMed ID: 13084478
    [No Abstract]   [Full Text] [Related]  

  • 11. Lifitegrast Ophthalmic Solution 5%: A Review in Dry Eye Disease.
    Keating GM
    Drugs; 2017 Feb; 77(2):201-208. PubMed ID: 28058622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The formulation of eye drops for the Australian and New Zealand Pharmaceutical Formulary.
    LOWE RF
    Trans Ophthalmol Soc Aust; 1954; 14():84-91. PubMed ID: 13256627
    [No Abstract]   [Full Text] [Related]  

  • 13. Efficacy and safety of diquafosol ophthalmic solution in patients with dry eye syndrome: a Japanese phase 2 clinical trial.
    Matsumoto Y; Ohashi Y; Watanabe H; Tsubota K;
    Ophthalmology; 2012 Oct; 119(10):1954-60. PubMed ID: 22739038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of textured eye drop bottles on the photostability of pranoprofen 0.1% ophthalmic solution.
    Iwatsuka K; Inada K; Ueoka H; Otsuka T; Maeda M; Yamaguchi M; Yasueda S
    Drug Dev Ind Pharm; 2015; 41(9):1526-31. PubMed ID: 25308744
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [NO NEED TO WASH THE EYES].
    MIZUKAWA T
    Nihon Ganka Kiyo; 1963 Aug; 14():235-7. PubMed ID: 14085317
    [No Abstract]   [Full Text] [Related]  

  • 16. [MICROBIOLOGICAL PURITY OF SOLUTIONS FOR INJECTIONS AND EYE DROPS].
    NIKOLAEVA EA; BOGDANOVA AM; STEPANOVA ZA
    Aptechn Delo; 1965; 14():64-8. PubMed ID: 14345306
    [No Abstract]   [Full Text] [Related]  

  • 17. Three percent diquafosol ophthalmic solution as an additional therapy to existing artificial tears with steroids for dry-eye patients with Sjögren's syndrome.
    Yokoi N; Sonomura Y; Kato H; Komuro A; Kinoshita S
    Eye (Lond); 2015 Sep; 29(9):1204-12. PubMed ID: 26160526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dermatological reactions to ophthalmic preparations: more than meets the eye.
    Byrom L; Zappala T; Muir J
    Australas J Dermatol; 2014 May; 55(2):95-8. PubMed ID: 24528088
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [CELESTONE -S OPHTHALMIC COLLOID].
    CRAMER FK; LAMELA NA
    Sem Med; 1963 Oct; 123():1177-8. PubMed ID: 14109318
    [No Abstract]   [Full Text] [Related]  

  • 20. CONTAMINATED OPHTHALMIC OINTMENTS.
    ANDERSON KF; CROMPTON DO; LILLIE S
    Trans Ophthalmol Soc Aust; 1963; 23():86-7. PubMed ID: 14237251
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.